- Trials with a EudraCT protocol (124)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
124 result(s) found for: Viral shedding.
Displaying page 1 of 7.
EudraCT Number: 2006-001611-30 | Sponsor Protocol Number: AJAE1001 | Start Date*: 2006-08-22 |
Sponsor Name:Hammersmith Hospital NHS Trust | ||
Full Title: Clinical trial comparing the effect of Acetaminophen and Ibuprofen on the duration of influenza viral shedding in young children (Pilot study) | ||
Medical condition: Influenza in children [positive rapid diagnostic test (QuickVue influenza test)confirmed by influenza PCR] Infants and young children shed the influenza virus for longer periods than adults, durat... | ||
Disease: | ||
Population Age: Infants and toddlers, Children, Under 18 | Gender: Male, Female | |
Trial protocol: GB (GB - no longer in EU/EEA) | ||
Trial results: View results |
EudraCT Number: 2016-003004-31 | Sponsor Protocol Number: NP25139 | Start Date*: 2016-08-09 |
Sponsor Name:F. Hoffmann-La Roche AG | ||
Full Title: An Open Label, Prospective, Pharmacokinetic/Pharmacodynamic and Safety Evaluation of Intravenous Oseltamivir (Tamiflu) in the Treatment of Children 1 to 12 Years of Age With Influenza Infection | ||
Medical condition: Influenza | ||
Disease: | ||
Population Age: Infants and toddlers, Children, Under 18 | Gender: Male, Female | |
Trial protocol: Outside EU/EEA | ||
Trial results: View results |
EudraCT Number: 2020-003690-21 | Sponsor Protocol Number: R10933-10987-COV-2067 | Start Date*: 2020-10-06 | |||||||||||
Sponsor Name:Regeneron Pharmaceuticals, Inc. | |||||||||||||
Full Title: A Master Protocol Assessing the Safety, Tolerability, and Efficacy of Anti-Spike (S) SARS CoV 2 Monoclonal Antibodies for the Treatment of Ambulatory Patients with COVID-19 | |||||||||||||
Medical condition: Coronavirus disease 2019 (COVID-19) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: RO (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2015-004042-26 | Sponsor Protocol Number: PrEP-CS-002 | Start Date*: 2015-11-17 | |||||||||||
Sponsor Name:hVIVO Services Limited | |||||||||||||
Full Title: A Phase II, Double-Blinded, Randomised, Controlled Study to Examine the Prophylactic Efficacy, Safety and Tolerability of PrEP-001 in Asthmatic Subjects Subsequently Challenged with Human Rhinoviru... | |||||||||||||
Medical condition: Human Rhinovirus (HRV-16) | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2016-001008-49 | Sponsor Protocol Number: NV22155 | Start Date*: 2016-09-30 | |||||||||||
Sponsor Name:F. Hoffmann-La Roche AG | |||||||||||||
Full Title: A randomized, multicenter trial of oseltamivir doses of 75 mg for 5 or 10 days versus 150 mg for 5 or 10 days in influenza patients with pandemic (H1N1) 2009 | |||||||||||||
Medical condition: Influenza | |||||||||||||
|
|||||||||||||
Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: Outside EU/EEA | |||||||||||||
Trial results: View results |
EudraCT Number: 2011-005929-49 | Sponsor Protocol Number: VX11-787-101 | Start Date*: 2012-02-20 | |||||||||||
Sponsor Name:Vertex Pharmaceuticals Incorporated | |||||||||||||
Full Title: A Phase 2a, Randomized, Double Blind, Placebo Controlled Study to Investigate the Effects of VX 787 Administered to Adult Volunteers Experimentally Inoculated with Live Influenza Virus | |||||||||||||
Medical condition: Influenza A | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2012-002413-19 | Sponsor Protocol Number: GS-US-218-0103 | Start Date*: 2012-10-15 | |||||||||||
Sponsor Name:Gilead Sciences, Inc. | |||||||||||||
Full Title: A Phase 2a, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety, Tolerability, and Efficacy of GS-5806 in Healthy Volunteers Infected with Respiratory Syncytial Virus (RSV-A Me... | |||||||||||||
Medical condition: Respiratory Syncytial Virus (RSV) Infection | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2021-000492-36 | Sponsor Protocol Number: HOPECOVID-19 | Start Date*: 2021-05-31 | |||||||||||
Sponsor Name:UCLouvain | |||||||||||||
Full Title: Home and Outpatients Precocious Eradication of COVID-19 | |||||||||||||
Medical condition: COVID-19 | |||||||||||||
|
|||||||||||||
Population Age: Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||
Trial protocol: BE (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2020-001437-12 | Sponsor Protocol Number: COVID-19_ASS | Start Date*: 2020-04-09 | |||||||||||
Sponsor Name:Fundació Hospital Universitari Vall d'Hebron - Institut de Recerca (VHIR) | |||||||||||||
Full Title: Random, controlled, open, one-site clinical trial in adult patients with COVID-19 severe pneumonia treated with immunomodulatory drugs | |||||||||||||
Medical condition: Severe COVID-19 pneumonia | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2016-003003-54 | Sponsor Protocol Number: NP25138 | Start Date*: 2016-08-09 |
Sponsor Name:F. Hoffmann-La Roche AG | ||
Full Title: An Open-label, Prospective, Pharmacokinetic/Pharmacodynamic and Safety Evaluation of Intravenous Oseltamivir in the Treatment of Infants Less Than One Year of Age With Influenza Infection | ||
Medical condition: Influenza | ||
Disease: | ||
Population Age: Newborns, Infants and toddlers, Under 18 | Gender: Male, Female | |
Trial protocol: Outside EU/EEA | ||
Trial results: View results |
EudraCT Number: 2017-000952-24 | Sponsor Protocol Number: Flu-shed | Start Date*: 2017-05-17 | |||||||||||
Sponsor Name:Public Health England | |||||||||||||
Full Title: Assessment of viral shedding in children previously in receipt of multiple doses of live attenuated influenza vaccine (LAIV) compared to influenza vaccine-naïve controls | |||||||||||||
Medical condition: N/A - the vaccine will be administered to children according to current DH Immunisation schedule for England. | |||||||||||||
|
|||||||||||||
Population Age: Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2009-010334-21 | Sponsor Protocol Number: Flu002 | Start Date*: 2009-04-17 |
Sponsor Name:Oxford University | ||
Full Title: A phase IIa study to assess the safety and efficacy of a new influenza vaccine candidate MVA-NP+M1 in healthy adults. | ||
Medical condition: Influenza | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: GB (Prematurely Ended) | ||
Trial results: View results |
EudraCT Number: 2018-002470-42 | Sponsor Protocol Number: FluSHED-2 | Start Date*: 2018-08-30 | |||||||||||
Sponsor Name:Imperial College London JRC Office | |||||||||||||
Full Title: Assessment of viral shedding week following administration of live attenuated influenza vaccine in children: FluSHED-2 study | |||||||||||||
Medical condition: Prevention of influenza infection through immunisation | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2020-002537-15 | Sponsor Protocol Number: R10933-10987-COV-2066 | Start Date*: 2020-10-06 | ||||||||||||||||
Sponsor Name:Regeneron Pharmaceuticals, Inc. | ||||||||||||||||||
Full Title: A Master Protocol Assessing the Safety, Tolerability, and Efficacy of Anti-Spike (S) SARS CoV 2 Monoclonal Antibodies for the Treatment of Hospitalized Patients with COVID-19 | ||||||||||||||||||
Medical condition: Coronavirus disease 2019 (COVID-19) | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: RO (Completed) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2006-006263-23 | Sponsor Protocol Number: ML20910 | Start Date*: 2006-12-05 | |||||||||||
Sponsor Name:ROCHE | |||||||||||||
Full Title: Efficacy of Oseltamivir treatment in laboratory- confirmed influenza: evaluation of effect on viral shedding and on serum and cytoplasmatic inflammatory cytokine concentration. | |||||||||||||
Medical condition: Influenza type A and B virus infection | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2012-000854-73 | Sponsor Protocol Number: TCN‐032‐002 | Start Date*: 2012-06-21 | ||||||||||||||||
Sponsor Name:THERACLONE SCIENCES, INC. | ||||||||||||||||||
Full Title: A PHASE 2A, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF TCN-032 (HUMAN MONOCLONAL ANTIBODY DIRECTED AGAINST THE M2 PROTEIN OF INFLUENZA A VIRUS) IN SUBJECTS CHALLENGED WITH H3N2 INFLUENZA A VIRUS | ||||||||||||||||||
Medical condition: Treatment of severe influenza A virus disease. | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults | Gender: Male, Female | |||||||||||||||||
Trial protocol: GB (Completed) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2016-002134-74 | Sponsor Protocol Number: FLU-v004 | Start Date*: 2016-07-27 | |||||||||||
Sponsor Name:PepTcell Limited (trade name SEEK) | |||||||||||||
Full Title: Phase IIb Study of the Efficacy of FLU-v, a Broad Spectrum Influenza Vaccine in an H1N1 Influenza Healthy Human Challenge Model | |||||||||||||
Medical condition: Influenza virus | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2017-004582-27 | Sponsor Protocol Number: RSV-MVA-013 | Start Date*: 2018-07-23 | |||||||||||
Sponsor Name:Bavarian Nordic A/S | |||||||||||||
Full Title: A Phase 2a Randomized, Double-blinded, Placebo-controlled Trial to assess the Safety, Immunogenicity, and Efficacy of the recombinant MVA-BN-RSV Vaccine against Respiratory Syncytial Virus Infectio... | |||||||||||||
Medical condition: Upper and lower respiratory tract infections caused by Respiratory Syncytical Virus | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: BE (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2015-000574-35 | Sponsor Protocol Number: VIS410-201 | Start Date*: 2015-04-27 | |||||||||||
Sponsor Name:Visterra, Inc. | |||||||||||||
Full Title: A Phase 2a Randomized, Double-blind, Placebo-controlled Study to Assess the Safety, Tolerability and Antiviral Activity of a Single Intravenous Dose of VIS410 in Healthy Subjects after a Viral Ino... | |||||||||||||
Medical condition: Influenza A (H1N1) infection | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: BE (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2015-004023-31 | Sponsor Protocol Number: LPS-Fluenz | Start Date*: 2016-01-06 |
Sponsor Name:Radboudumc | ||
Full Title: The effects of endotoxin challenge on the immune response elicited by a subsequent challenge with Fluenz™ in healthy volunteers, a pilot study | ||
Medical condition: Inflammatory conditions in general and immunosuppressive conditions is particular | ||
Disease: | ||
Population Age: Adults | Gender: Male | |
Trial protocol: NL (Completed) | ||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
